THE TYSABRI CHANNEL

WE HAVE 2 NEW TYSABRI EDITORS STARTING 4/15/10! THEY WIL BE POSTING TYSABRI NEWS EVERY DAY!

Monday, May 12

HERE'S 12 HEADLINES FROM TODAY'S MS NEWS!

Tonsillectomy, Appendectomy Linked to Increased MS Risk

Brain Imaging in Multiple Sclerosis  

What Risks Are MS Patients Willing to Take for Improvement?

TYSABRI: JCV Test Stratifies PML Risk in Antibody-Positive MS

ANOTHER NEW MS DRUG: Siponimod for Relapsing-Remitting MS

Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis

Natalizumab inhibits the expression of human endogenous retroviruses of theW family in multiple sclerosis patients: a longitudinal cohort study

Tumefactive multiple sclerosis lesions under fingolimod treatment

Therapeutic Decision Making in a New Drug Era in Multiple Sclerosis 

Alemtuzumab (Lemtrada) Gets Positive Opinion supporting marketing authorization for the treatment of relapsing-remitting multiple sclerosis. 

Ophthalmologic Manifestations of Multiple Sclerosis 

JCV Test 'Useful But Not Sufficient' to Gauge PML Risk


Posted by YNergy at 5/12/2014 07:45:00 AM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: Lemtrada
Newer Post Older Post Home
Awesome Inc. theme. Powered by Blogger.